Original studyMetabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non–Small-Cell Lung Cancer
Introduction
Lung cancer is the leading cause of cancer death in both men and women in the United States1 and worldwide.2 While numerous prognostic factors have been identified including age, Karnofsky Performance Status (KPS), and weight loss,3 stage at presentation remains the most useful prognostic factor.4 As fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging has become part of the standard of care for staging patients with lung cancer, metabolic imaging parameters have been studied as potential prognostic factors. Studies have found that tumor metabolic activity, as estimated by the standardized uptake value (SUV), is a prognostic factor in patients with non–small-cell lung cancer (NSCLC),5 but it has not been universally found independently prognostic compared to other factors such as stage and tumor size.6 A possible reason for this discrepancy is that SUV does not fully represent a patient's metabolic tumor burden. Recently, we showed that metabolic tumor volume (MTV), or the volume of tumor tissue demonstrating increased FDG uptake on PET, is a novel and independent adverse prognostic factor in a small, heterogeneous cohort of patients with lung cancer, including those with localized as well as metastatic disease.7
Nevertheless, the role of PET-MTV as a prognostic factor in patients with lung cancer remains to be clarified. For example, it is unknown to what degree MTV is prognostic in a more specific subpopulation of patients such as those with localized lung cancer who are treated with a curative or definitive intent. The objective of this study was to investigate the value of MTV as an independent prognostic factor in lung cancer for overall survival (OS) and progression-free survival (PFS) in a larger cohort of patients with lung cancer, as well as in the subset of patients treated with definitive intent.
Section snippets
Patient Selection
We conducted a retrospective review of the medical records of patients who underwent combined PET and computerized tomography (FDG-PET-CT) imaging at Stanford Hospital and Clinics. We conducted this study under the review and approval of the Stanford institutional review board. Between January 2003 and June 2005, 325 patients with NSCLC and small-cell lung cancer (SCLC) were evaluated with diagnostic PET-CT scans. Of the 325 patients, 66 had an initial staging scan before the initiation of
Patient Characteristics
Medical records of these 61 patients were reviewed for patient age, sex, tumor histology, date of initial PET-CT scan, American Joint Committee on Cancer (AJCC) stage (TNM), treatment type, treatment intent, date of treatment, radiation dose and target volume, date of local recurrence, date of distant progression, date of last follow-up, KPS, and weight loss. These characteristics are summarized in Table 1.
Among the 61 patients in this study, 39 were treated with definitive intent, while 22
Discussion
We based this study on the hypothesis that MTV is an independent prognostic factor for overall outcome in lung cancer after controlling for established variables such as clinical stage. Stage stratifies patients into only four categories of disease extent, within each of which there is a wide range of volumetric tumor burden and presumably prognosis.11 This was true in our cohort as well (Figure 3). CT-based gross tumor volume (GTV), as segmented manually for 3-dimensional conformal radiation
Disclosure
Conflict of interest: Percy Lee has received speaking honorarium from BrainLAB Medical Systems. Billy W. Loo, Jr, has received speaking honoraria from Varian Medical Systems, Accuray, and General Electric Medical Systems. None of the other authors have financial or personal conflicts of interest to disclose. The authors had full access to all of the data in the study and take complete responsibility for the integrity of the data and the accuracy of the data analysis.
References (21)
- et al.
Prognostic factors in non-small cell lung cancer: a decade of progress
Chest
(2002) - et al.
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours
J Thorac Oncol
(2007) - et al.
Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project
J Thorac Oncol
(2010) - et al.
Metabolic tumor burden predicts for disease progression and death in lung cancer
Int J Radiat Oncol Biol Phys
(2007) - et al.
Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database
J Thorac Oncol
(2006) - et al.
Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma
Int J Radiat Oncol Biol Phys
(2002) - et al.
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy
Int J Radiat Oncol Biol Phys
(2008) - et al.
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer
Int J Radiat Oncol Biol Phys
(2009) - et al.
Cancer statistics, 2009
CA Cancer J Clin
(2009) - et al.
Global cancer statistics, 2002
CA Cancer J Clin
(2005)
Cited by (87)
Is there any improvement in clinical staging with <sup>18</sup>F-FDG PET/CT compared to surgical staging in cases of lung cancer?
2019, Revista Espanola de Medicina Nuclear e Imagen MolecularIncreases in Serial Pretreatment <sup>18</sup>F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy
2019, Advances in Radiation OncologyCitation Excerpt :Prior studies have identified the predictive value of quantitative metrics on planning PET/CT. High pretreatment maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) are predictive of disease progression and death.9-11 Temporal changes in these parameters obtained from serial pretreatment PET/CT scans, expressed as SUV velocity (SUVV) and metabolic tumor growth rate (MTGR), might provide additional prognostic information as imaging correlates to tumor grade12 and tumor doubling time,13 respectively, which are known predictors of survival.14-16
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/ computed tomography for predicting prognosis of small cell lung cancer patients
2023, International Journal of Radiation Research
Percy Lee and Jose G. Bazan contributed equally to this work